Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Workers with rheumatoid arthritis incur increased health-related costs

Workers with rheumatoid arthritis (RA) incur increased direct and indirect health-related costs, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

5 Mar 2013

Biogen announces FDA acceptance of rFIXFc BLA for treatment of hemophilia B

Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B and granted the company a standard review timeline.

5 Mar 2013

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.

4 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Tooth loss due to periodontal disease is more prevalent among postmenopausal women

Postmenopausal women who have smoked are at much higher risk of losing their teeth than women who never smoked, according to a new study published and featured on the cover of the Journal of the American Dental Association by researchers at the University at Buffalo.

2 Mar 2013

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

$Bisphosphonate link to nonhealing fractures strengthened$

Bisphosphonate link to nonhealing fractures strengthened

US scientists have identified a safety signal between bisphosphonate use and nonhealing femoral fractures, possibly due to the rare side effect, atypical femur fracture.

1 Mar 2013

FDA accepts Antares Pharma's New Drug Application for OTREXUP

Antares Pharma, Inc. today announced that the New Drug Application for OTREXUP, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

27 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Allergan receives FDA approval for Natrelle 410 breast implant

The U.S. Food and Drug Administration today approved the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Gel Filled Breast Implant to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. Natrelle 410 implants are manufactured by Allergan, Inc.

20 Feb 2013

Regeneron fourth quarter total revenues increase to $415 million

Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

14 Feb 2013

Combination of Methotrexat and Tofacitinib shows promise against rheumatoid arthritis

Together with colleagues from the international rheumatic diseases research community, scientists of the Charité - Universitätsmedizin Berlin have presented a new therapy approach for the treatment of rheumatoid arthritis (RA), a chronic form of joint inflammation.

14 Feb 2013

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

13 Feb 2013

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

March is National Autoimmune Disease Awareness Month 2013. To mark the annual event, the American Autoimmune Related Diseases Association Inc. (AARDA) is encouraging the national and local media around the country to report stories on autoimmune diseases (AD) and autoimmunity as a category of disease.

13 Feb 2013

UV prevention measures may influence rheumatoid arthritis incidence

Increased ultraviolet-B exposure reduces the risk for rheumatoid arthritis in women, US researchers suggest, but the drive to protect against skin cancer in recent years may have negated this benefit.

12 Feb 2013

CD8+ Tregs can remove pathogenic T cell subsets and inhibit progression of RA

Rheumatoid arthritis (RA) is an autoimmune disorder in which immune cells attack the joints, causing inflammation, swelling, and erosion. Specific sets of immune cells, known as T cells, are responsible for inducing disease. In this issue of the Journal of Clinical Investigation, researchers led by Harvey Cantor at Harvard University analyzed the contributions of different subsets of T cells to an RA-like condition in mice.

11 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

CEL-SCI reports net loss of $2,310,246 for fiscal quarter ended December 31, 2012

CEL-SCI Corporation reports financial results for the fiscal quarter ended December 31, 2012.

10 Feb 2013

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Workers with rheumatoid arthritis incur increased health-related costs

Biogen announces FDA acceptance of rFIXFc BLA for treatment of hemophilia B

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Tooth loss due to periodontal disease is more prevalent among postmenopausal women

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Bisphosphonate link to nonhealing fractures strengthened

FDA accepts Antares Pharma's New Drug Application for OTREXUP

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Allergan receives FDA approval for Natrelle 410 breast implant

Regeneron fourth quarter total revenues increase to $415 million

Combination of Methotrexat and Tofacitinib shows promise against rheumatoid arthritis

Antibody therapeutics targeting GPCRs to be developed by alliance between MorphoSys and Heptares

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

UV prevention measures may influence rheumatoid arthritis incidence

CD8+ Tregs can remove pathogenic T cell subsets and inhibit progression of RA

Infusions of regulatory T cells turn off autoimmune attack on joints

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

CEL-SCI reports net loss of $2,310,246 for fiscal quarter ended December 31, 2012

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in